Mycoplasma pneumonia is treated with a specific class of antibiotics called macrolides, which are considered the first-line treatment for both children and adults. Unlike typical bacterial pneumonia, mycoplasma doesn’t respond to the penicillin-type antibiotics most people are familiar with, so getting the right prescription matters. Most cases are mild enough to recover at home with antibiotics and supportive care, earning it the nickname “walking pneumonia.”
Why Standard Antibiotics Don’t Work
Mycoplasma pneumoniae is an unusual bacterium. It lacks a cell wall, which is the structure that common antibiotics like amoxicillin target to kill bacteria. This means the entire penicillin family of drugs, the most commonly prescribed antibiotics in the world, is completely ineffective against mycoplasma. If you’ve been treated for pneumonia with a standard antibiotic and aren’t improving, mycoplasma could be the reason.
Diagnosing mycoplasma specifically helps guide the right treatment. The CDC identifies molecular testing (called nucleic acid amplification tests) as the preferred diagnostic method because it’s both highly accurate and fast enough to guide treatment decisions. Older blood-based tests that look for antibodies lack specificity and often require two separate blood draws weeks apart, making them less practical. Culture testing exists but is slow and only performed by specialized labs.
First-Line Antibiotic Treatment
Macrolide antibiotics are the treatment of choice for mycoplasma pneumonia. Azithromycin is the most commonly prescribed macrolide because of its convenient dosing schedule, typically a five-day course. Clarithromycin is another macrolide option. These drugs work by blocking the bacterium’s ability to produce proteins it needs to survive and multiply.
For older children and adults, tetracycline-class antibiotics (such as doxycycline) serve as an effective alternative, particularly in areas where macrolide resistance is a concern. Fluoroquinolone antibiotics are reserved for adults only. Both tetracyclines and fluoroquinolones should not be prescribed to young children under normal circumstances due to potential side effects on developing bones and teeth.
Your doctor will consider your age and local resistance patterns when choosing which antibiotic to prescribe. In most cases, you’ll take a full oral course at home without needing any IV medications or hospital visits.
Macrolide Resistance: A Growing Concern
One complication in treating mycoplasma is that some strains have developed resistance to macrolide antibiotics. A 2025 study tracking a pediatric outbreak in Ohio found macrolide resistance in 4.5% of samples overall, with monthly rates fluctuating between 0% and 8.7%. The resistance rate correlated with how frequently azithromycin was being prescribed in the community, reinforcing that overuse of these drugs drives resistance.
Resistance rates vary significantly by region. In parts of East Asia, macrolide resistance has historically been much higher than in North America. If you or your child aren’t improving after two to three days on a macrolide, resistance could be the issue. In these cases, your doctor will typically switch to a tetracycline (for older children and adults) or a fluoroquinolone (for adults).
Managing Symptoms at Home
Antibiotics target the infection itself, but much of what makes you feel miserable requires separate management. Fever and body aches respond well to over-the-counter pain relievers like acetaminophen or ibuprofen. Staying well-hydrated helps thin mucus and supports your body’s immune response. Warm liquids, honey (for anyone over age one), and a humidifier can ease throat irritation and make coughing less painful.
Rest is genuinely important, not just a polite suggestion. Mycoplasma pneumonia taxes your respiratory system even when it feels manageable, and pushing through normal activities can prolong recovery. Most people feel well enough to return to work or school within a week of starting antibiotics, but full energy may take longer to return.
What Recovery Looks Like
The most frustrating part of mycoplasma pneumonia for most people is the lingering cough. Even after the infection has been successfully treated, your cough can persist for two to three weeks. This happens because the airways remain irritated and inflamed after the bacteria are gone. It doesn’t mean the antibiotics failed or the infection is still active.
If your cough or wheezing hasn’t improved after two to four weeks, that warrants a follow-up with your doctor. In rare cases, the infection can trigger reactive airway disease (temporary asthma-like symptoms) that needs additional treatment, or the initial diagnosis may need to be reconsidered. Fever should resolve well before the cough does. If fever returns or worsens after initially improving on antibiotics, contact your doctor promptly.
When Hospital Care Is Needed
The vast majority of mycoplasma pneumonia cases resolve at home. However, certain people, particularly those with asthma, weakened immune systems, or chronic lung conditions, can develop more severe illness. Hospital admission becomes necessary when oxygen levels drop or breathing becomes significantly labored.
For most acute medical conditions including pneumonia, oxygen supplementation is initiated when blood oxygen saturation drops below 92%, with a target range of 92% to 96%. If you have a pulse oximeter at home and see readings consistently below 92%, or if you’re experiencing rapid breathing, chest pain, or confusion, seek emergency care. Respiratory rate is considered a key predictor of serious clinical events, so breathing that feels noticeably fast or effortful at rest is a meaningful warning sign.
People with chronic lung disease like COPD have different oxygen thresholds, with treatment starting below 88% and targeting a range of 88% to 92%, because too much supplemental oxygen can actually be harmful in these conditions.
Children and Mycoplasma Pneumonia
Mycoplasma pneumonia is especially common in school-age children and young adults, typically those between ages 5 and 20. Following the COVID-19 pandemic, mycoplasma reemerged significantly in the pediatric population as social mixing patterns returned to normal and children encountered the bacterium without the partial protection that prior exposure provides.
Treatment for children follows the same general approach: macrolide antibiotics are first-line. The key difference is that the backup options are more limited. Tetracyclines are only appropriate for older children, and fluoroquinolones are generally avoided entirely in pediatric patients. This makes macrolide resistance a more pressing concern in younger children, since there are fewer safe alternatives if the first-choice antibiotic doesn’t work. If your child isn’t improving on a macrolide, their doctor can help determine whether switching antibiotics or further testing is the right next step.